StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Depomed (DEPO) to Acquire U.S. Rights to Cosyntropin, Divest Lazanda in Pact with Slan
November 7, 2017 4:03 PM
Depomed Inc. (NASDAQ: DEPO) announced today that it has entered into an agreement with Slán Medicinal Holdings Limited (“Slán”) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
Management Comments
Mergers and Acquisitions
Next Articles
DepoMed Inc (DEPO) PT Lowered to $6 at RBC Capital Following 3Q Miss
November 8, 2017 8:13 AM
Depomed and Slán Medicinal Holdings Ltd Announce Strategic Asset Transactions
November 7, 2017 4:00 PM